Illumina: Unlocking the Power of Genome

Pharma Tech Outlook: Pharma Tech Magazine

Illumina: Unlocking the Power of Genome

Follow Illumina on :

Francis deSouza, President and CEO, Illumina Francis deSouza, President and CEO
The exponential expansion of the genomics realm comes with increased complexities that demand the application of mission-critical, innovative technologies and groundbreaking assays to genetic variation and function analysis. In line with these growing needs, Illumina was founded with a mission to improve human health by enabling researchers and scientists with a better understanding of genetic variation at all the levels of complexities.

A developer, manufacturer, and marketer of integrated systems for analysis of genetic variation and biological function, Illumina provides a comprehensive line of products and services that help researchers to explore DNA at an entirely new scale. These products and services assist genomic research centers, pharmaceutical companies, academic institutions, and biotechnology companies in sequencing, genotyping and marking gene expression. From genetic health, food safety to cancer research, Illumina’s breakthrough solutions enable researchers to select the best solution for their scientific challenge.

Standing at the intersection of biology and technology, Illumina has designed leading-edge, simple, more accessible, and reliable sequencing and array-based solutions that mitigate the scale of experimentation and functional analysis to advance disease research, drug development, and the development of molecular tests. The extensive range of solutions and services include sequencing platforms to sequence DNA and RNA, microarray scanners to screen tools for analyzing genetic variation, next-generation sequencing (NGS) to study biological system, and BaseSpace Informatics Suite to remove common informatics barriers.

Illumina provides a sequencing technology that enables researchers to perform a wide variety of applications and study biological system. NGS delivers information that was beyond the capacity of traditional DNA sequencing technologies to researchers.
The platform allows the researchers to expediently sequence whole genomes, vastly explore the deep sequence target regions, analyze epigenetic factors such as genome-wide DNA methylation and DNA-protein interactions, and much more. NGS has the capability to deliver exceptional data quality and accuracy, at the scale that its clients’ needs.

iSeq 100 provides robustness and dependability for a broad range of applications ranging from germline and somatic tumor categorizing to 16S microbial analysis and targeted gene expression

Illumina’s sequencing enables a wide variety of sequencing reagents, the iSeq 100 Sequencing System, in particular, makes a more accessible and affordable NSG, as it allows labs of all sizes to sequence DNA and RNA feasibly. Harnessing the speed and affordability of complementary metal-oxide-semiconductor (CMOS) technology and the accuracy of sequencing by synthesis (SBS) chemistry, the iSeq 100 System enables virtually any lab to acquire powerful next-generation sequencing (NGS) technology. “The iSeq 100 provides robustness and dependability for a broad range of applications ranging from germline and somatic tumor categorizing to 16S microbial analysis and targeted gene expression,” says Francis deSouza, President and CEO at Illumina.

To meet diverse research needs, Illumina is developing microarrays for surveying thousands of samples to identify point mutations, structural variants, or changes in gene expression and methylation. Powered by Infinium technology, Illumina microarrays aid the researchers with genetic variant detection straight from discovery applications to routine screening. Illumina microarrays offer several advantages over other microarrays as it provides trusted data quality and built-in lab management, tracking, and traceability tools. These microarrays help detect the chromosomal alterations and copy number variation and also integrate with Illumina sequencing systems for multi-omics analyses.

Illumina finds a unique place in the industry by placing a high value on collaborative interactions for rapid delivery of solutions. Illumina will continue its endeavor to make their solutions increasingly simple enabling their clients to read and understand genetic variations efficiently. With the ability to sequence at an unprecedented scale, the company aims to trigger a fundamental shift in the healthcare realm, meanwhile transforming human health.
Share this Article:
Top 10 Genomics Solution Companies – 2020


San Diego, CA

Francis deSouza, President and CEO

Illumina specializes in applying innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for the company to deliver innovative, flexible, and scalable solutions to meet the needs of its customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, Illumina strives to meet this challenge. Its innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics